Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Cancer Research

Background:

• Englerin A is a potent and selective natural product for renal cancer cells.
• Modifications at the bridgehead position are explored to understand structure-activity relationships.

Purpose of the Study:

• To investigate the impact of bridgehead modifications on englerin A's biological activity.
• To synthesize and evaluate novel englerin A analogs for anticancer properties.

Main Methods:

• Synthesis of englerin A analogs with varied bridgehead substituents.
• Anticancer activity assessment using the NCI 60 cancer cell line screen.
• Evaluation of TRPC4 ion channel activity and in vivo intravenous toxicity in mice.

Main Results:

• Modified compounds retained high selectivity and potency comparable to englerin A.
• Replacement of the isopropyl group with larger substituents was well-tolerated.
• Selected analogs exhibited reduced potency against TRPC4 and lower intravenous toxicity.

Conclusions:

• Bridgehead modifications can yield potent and selective englerin A analogs.
• The bridgehead position is crucial for maintaining anticancer activity.
• Further optimization may be needed to balance potency, selectivity, and safety profiles.